EU Pharma Loses €10.2bn, 38,000 Jobs To Counterfeits As “Massive” Track & Trace Obligations Approach
As a new report reveals that 4.4% of legitimate sales of drugs are lost each year in the EU due to counterfeiting, drug companies are being warned not to underestimate how much work they will need to do to comply with new track and trace rules.
You may also be interested in...
New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.
The new EU rules on the safety feature to be attached to almost all prescription medicines have finally been published, and once they kick in products will have to carry a 'unique identifier' in the form of a 2D bar code on the pack that will allow its authenticity to be verified1.
NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.